“…Currently, three drugs, acamprosate, naltrexone, and disulfiram, have received FDA approval for the pharmacotherapy of AUD in the United States. However, a growing body of evidence suggests a potential role for FGF21 as a novel treatment target for AUD [ 4 , 7 ]. We designed the present study to apply GWAS to identify genetic variants that might be associated with plasma FGF21 levels and to study their possible functional role in AUD.…”